COMPANY OVERVIEW
CN Bio Innovations, headquartered in Cambridge, UK, develops the PhysioMimix multi-organ microphysiological system platform. Spun out from the University of Oxford in 2009, the company enables pharmaceutical companies to study drug metabolism, efficacy, and toxicity using interconnected human organ models, reducing reliance on animal testing and improving clinical translation.
PHYSIOMIMIX PLATFORM
- PhysioMimix MPS: Multi-organ system enabling ADME-Tox studies with perfusion
- Liver Models: Primary hepatocyte and hepatic cell line platforms maintaining function 28+ days
- Gut-Liver Axis: Connected intestine and liver for first-pass metabolism modeling
- Multi-Organ: Up to 7 interconnected organ compartments for systemic studies
- Open-Well Design: Compatible with standard liquid handling and imaging
KEY APPLICATIONS
- Drug-induced liver injury (DILI) prediction and mechanistic studies
- ADME-Tox profiling including metabolite identification
- First-pass metabolism for oral drug bioavailability
- Drug-drug interaction assessment
- NASH/NAFLD disease modeling with steatosis endpoints
PHARMA PARTNERSHIPS
CN Bio partners with major pharmaceutical companies including AstraZeneca, GSK, Roche, and Takeda for preclinical drug development programs. The company also supplies systems to academic centers and CROs for contract research services.